

CLAIMS

1. A method of decreasing atherosclerosis and its complications including but not limited to myocardial infarction, stroke and peripheral vascular disease comprising administering to an animal or human an amount of a substance which acts to decrease the levels of testosterone or which inhibits the actions of testosterone.

2. A method of decreasing atherosclerosis and its complications including but not limited to myocardial infarction, stroke and peripheral vascular disease comprising administering to a human or an animal an amount of a substance which is an inhibitor of the release of LHRH or GnRH, or any substance which inhibits the action or effects of LHRH, resulting in decreased levels of LH (luteinizing hormone).

3. A method of decreasing atherosclerosis and its complications including but not limited to myocardial infarction, stroke and peripheral vascular disease comprising administering to an animal or human an amount of Finasteride or other inhibitor of 5 alpha reductase inhibitor or an inhibitor of any subtype of that enzyme resulting in decreased levels of dihydrotestosterone (DHT), in an amount sufficient to reduce atherosclerosis.

4. A method of decreasing atherosclerosis and its complications including but not limited to myocardial infarction, stroke and peripheral vascular disease

comprising administering to an animal or human an amount of non-steroidal antiandrogen sufficient to reduce atherosclerosis.

5. The method of Claim 4 comprising administering to a human or an animal an amount of Bicalutamide sufficient to reduce atherosclerosis.

6. The method of Claim 5 wherein the effective amount of Bicalutamide is 50 mg as an oral tablet taken daily.

7. The method of Claim 5 wherein Bicalutamide is administered as a tablet, or as part of a liquid solution or dispersion, or patch, or subcutaneous pellet, or intramuscular injection, or any other method with the intent of accomplishing systemic absorption of the drug sufficient to reduce atherosclerosis.

8. The method of Claim 4 comprising administering to a human or an animal an amount of Flutamide sufficient to reduce atherosclerosis.

9. The method of Claim 8 wherein the effective amount of Flutamide is 250 mg orally three times a day.

10. The method of Claim 5 wherein Flutamide is administered as a tablet, or as part of a liquid solution or dispersion, or patch, or subcutaneous pellet, or intramuscular injection, or any other method with the intent of accomplishing systemic absorption of the drug sufficient to reduce atherosclerosis.

11. The method of Claim 4 comprising administering to a human or an animal an amount of Nilutamide sufficient to reduce atherosclerosis.

12. The method of Claim 11 wherein the effective amount of Nilutamide is 50 mg orally three times a day.

*a* 13. The method of Claim 11 wherein Nilutamide is administered as a tablet, or as part of a liquid solution or dispersion, or patch, or subcutaneous pellet, or intramuscular injection, or any other method with the intent of accomplishing systemic absorption of the drug sufficient to reduce atherosclerosis.

14. A method of decreasing atherosclerosis and its complications including but not limited to myocardial infarction, stroke and peripheral vascular disease comprising administering to an animal or human an amount of a substance sufficient to decrease or inhibit synthesis of testosterone.